A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-05. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== Further reading == Fitzgerald J, Bateman JF (September 2001). "A new FACIT of the collagen family: COL21A1". FEBS Letters. 505 (2): 275–280. doi:10.1016/S0014-5793(01)02754-5. PMID 11566190. Chou MY, Li HC (March 2002). "Genomic organization and characterization of the human type XXI collagen (COL21A1) gene". Genomics. 79 (3): 395–401. doi:10.1006/geno.2002.6712. PMID 11863369.
Ibogaine is derived from the root of Tabernanthe iboga, a plant known to exhibit hallucinogenic effects in people who consume it. It is described as having a typical dose range of 1,000 to 1,500 mg orally, with these doses producing hallucinogenic effects, and a duration of 18 to 36 hours. However, lower doses like 200 to 400 mg orally are also active and said to be hallucinogenic. In addition, very low doses of ibogaine, like 8 to 50 mg orally, have been used and reported to produce stimulant or "antidepressant" effects. The onset of the drug is 1 to 3 hours and peak effects have been described as being reached after 2 hours. With full hallucinogenic doses, ibogaine is described as having three different phases of effects. The first phase is the acute or visionary phase, which onsets after 1 to 3 hours and has a duration of 4 to 8 hours; the second phase is the evaluative or introspective phase, which starts after 4 to 8 hours and has a duration of 8 to 20 hours; and the third phase is residual stimulation, which onsets after 12 to 24 hours and has a duration of 24 to 72 hours or longer. Each of these phases is described as having distinct qualitative effects. The visionary phase is a dream-like, conscious state called oneirophrenia. Visual effects are almost always present and are often described as films or slideshows. These may be accompanied by increases in long-term visual memory, resulting in autobiographical content. Other changes to sensation and perception may occur, including auditory hallucinations or distortions. Nausea and vomiting can be severe.
freeway removal incentives, heavy-duty alternative fuel vehicle grants, grants for training contractors to perform home electrifications, grants for environmental justice promotion, grants for improvements to state and local environmental impact assessment capacity, and the EPA's green bank, the Greenhouse Gas Reduction Fund.
=== United States (1804) === On 29 April 1804, Alexander von Humboldt, accompanied by Bonpland and Monttfar, embarked from Havana on the Spanish frigate Concepcion en route to Philadelphia. They endured a week-long storm in the Bahama Straits, raising concerns for the safety of their scientific collections. After 24 days, they reached the calm waters of Delaware, where they had their first views of the United States. The landscape featured low, forest-covered shores punctuated with marshland, and as they neared Philadelphia, attractive farmhouses came into sight amidst the forest clearings. However, upon closer approach, the waterfront revealed an unsightly scene of wooden warehouses and refuse. Behind this façade lay a well-organized city of 75,000 residents, reminiscent of European towns. Its cobblestone streets lined with poplar trees, elegant three-storey red-brick houses, and well-furnished interiors stood in stark contrast to the initial impression. The main public building, aside from the State House, was Philosophic Hall, home to the American Philosophical Society, which played a crucial role in arranging for Humboldt's visit. Despite Philadelphia losing its capital status to Washington, it remained the cultural and scientific heart of the burgeoning republic. Humboldt and his companions were accommodated in an inn near the harbor on Market Street, and their arrival was promptly covered in the local newspapers.
==== Gliding lizards ==== There are two different mechanisms by which lizards glide through the air. Both mechanisms involve the patagia. In the active mechanism, skeletal supports and muscles run through the patagia of lizards. The skeletal supports and muscle erect the flight membrane and control the gliding using the patagia. Most of the lizards that exhibit this active gliding mechanism are agamine lizards such lizards in the genus Draco. For the passive mechanism of gliding in lizards, the patagia is unfurled by air pressure alone. The patagia of the passive mechanism differs from patagia of the active mechanism; there is the lack of skeleton support and musculature in patagia of the gliding lizards with the passive gliding mechanism. The passive mechanism of gliding is seen in smaller lizards such as the geckos of the genus Ptychozoon. For the passive mechanism of gliding, body movements are believed to control the descent of the gliding lizard. The surface area to body ratios of lizards with different gliding mechanisms are similar, but how the surface area is distributed is different. The difference in the distribution of surface area indicates the differences in the role of the patagia and accessory areas for the different flight mechanisms. Lizards with passive gliding mechanisms tend to have smaller patagia relative to lizards with active flight mechanisms. However, lizards with passive flight mechanism have, ore surface area located in accessory areas (i.e. webbed toes, tail) than lizards with the active gliding mechanism.
Sources: en.wikipedia.org
== Research and advocacy == The Muscular Dystrophy Association (MDA) is involved in research, advocacy, and services for individuals affected by muscular dystrophy. The organization provides resources that contribute to understanding and addressing this condition.
33rd Street between Seventh and Eighth Avenues was converted into a pedestrian plaza and permanently closed to vehicular traffic, opening in June 2024 as part of a $65 million project funded by Vornado.
Danyelle M. Townsend is a biomedical scientist, and academic. She is a Professor and acting Department Chair of Drug Discovery and Biomedical Sciences at the Medical University of South Carolina (MUSC). Townsend's lab utilizes proteomics and analytical biochemistry to identify molecular targets affected by oxidative and nitrosative stress, exploring the impact of redox signaling on cellular responses. Her research on the redox proteome and associated pathways has contributed to drug discovery and redox biomarker development. Townsend has authored over 150 peer-reviewed publications including journal articles, book chapters, and co-edited a book titled, Redox and Cancer Part A. In addition, she served as Co-Editor for Biomedicine and Pharmacotherapy from 2014 to 2015, and has been the Editor-in-Chief for this journal since 2015.
== Early life == Daveigh Elizabeth Chase-Schwallier was born on July 24, 1990, in Las Vegas, Nevada, to Cathy Chase and John David Schwallier. She was young when her parents divorced. Each remarried, and she grew up with several half-siblings, including a younger half-brother named Cade. Chase later used her mother's maiden name professionally. She subsequently relocated with her mother to Albany, Oregon, where she performed in local talent shows and pageants. Her early vocal performances were centered on country music, for which she won a national vocal competition during her childhood. During a stay in Los Angeles, Chase began attending casting calls and booking minor roles, including national television advertising spots at age seven for the Campbell's Soup Company. Chase appeared in a regional theatrical production of the musical Utah! at the Tuacahn Amphitheatre in 1998, sharing the role of Norma Sanderson. She credited this stage experience with refining her live singing ability and performance presence.
=== Use of nuclear properties === A technique similar to radioisotopic labeling is radiometric dating: using the known half-life of an unstable element, one can calculate the amount of time that has elapsed since a known concentration of isotope existed. The most widely known example is radiocarbon dating used to determine the age of carbonaceous materials. Several forms of spectroscopy rely on the unique nuclear properties of specific isotopes, both radioactive and stable. For example, nuclear magnetic resonance (NMR) spectroscopy can be used only for isotopes with a nonzero nuclear spin. The most common nuclides used with NMR spectroscopy are 1H, 2D, 15N, 13C, and 31P. Mössbauer spectroscopy also relies on the nuclear transitions of specific isotopes, such as 57Fe. Radionuclides also have important uses. Nuclear power and nuclear weapons development require relatively large quantities of specific isotopes. Nuclear medicine and radiation oncology utilize radioisotopes respectively for medical diagnosis and treatment.
Sources: en.wikipedia.org
Romergoline (INNTooltip International Nonproprietary Name; developmental code name FCE-23884) is a dopamine receptor modulator of the ergoline family which was under development for the treatment of Parkinson's disease and psychotic disorders but was never marketed. It is closely related to the psychedelic drug LSD in terms of chemical structure, though it is not technically a lysergamide itself as the oxygen atom of LSD's carboxamide moiety has been removed to instead form an aminomethyl moiety.
26 October In two studies, scientists report findings about the role of epigenetics – which is shaped during lifetime – in colorectal cancer, including that it is a major component of how an individual tumor varies and findings about its influences on the accumulation of DNA mutations and cancer phenotypes. At the 30th anniversary of the World Scientists' Warning to Humanity, scientists conclude that "We are now at 'code red' on planet Earth", facing a climate emergency, warning citizens and world leaders to take necessary actions with information about tracked "recent climate-related disasters, assess[ed] planetary vital signs, and [...] policy recommendations". A study concludes that cosmic radiation events in the tree-ring radiocarbon record called "Miyake events", don't appear to be caused by the solar cycle (i.e. solar flares) as thought previously and have extended durations. They occurred every ~1,000 years on average and may threaten global technologies this century. A magnetical guidance system with engineered bacterial microbots (see also 22 September above) for 'precision targeting' is demonstrated to be effective for fighting cancer in mice. 31 October Multiple traces of monkeypox are detected in non-sewered wastewater with sparse sampling from a densely populated metropolitan area in Asia. A new record for the longest-frozen embryos to ever result in a live birth is reported in the United States, with twins born after storage for 30 years.
RI + (CH3CH2)3N → [(CH3CH2)3NR]+I− Triethylamine is mainly used in the production of quaternary ammonium compounds for textile auxiliaries and quaternary ammonium salts of dyes. It is also a catalyst and acid neutralizer for condensation reactions and is useful as an intermediate for manufacturing medicines, pesticides and other chemicals. Triethylamine salts, like any other tertiary ammonium salts, are used as an ion-interaction reagent in ion interaction chromatography, due to their amphiphilic properties. Unlike quaternary ammonium salts, tertiary ammonium salts are much more volatile, therefore mass spectrometry can be used while performing analysis.
However, this method is not truly analogous to protein structural alignment techniques because it computationally predicts the structures of the RNA input sequences rather than requiring experimentally determined structures as input. Although computational prediction of the protein folding process has not been particularly successful to date, RNA structures without pseudoknots can often be sensibly predicted using free energy-based scoring methods that account for base pairing and stacking.
This enabled them to make a number of major technological improvements, including the introduction of fiber suppressors (1981), a metal-free system eliminating sources of contamination and corrosion (1981), integrated workstation and process analysis capabilities (1984), suppressors for gradient elution (1986) and accelerated solvent extraction (1995). These technological changes made it possible for scientists to detect ionic materials quickly at extremely low levels of concentration. This increased both the sensitivity of the tests that it was possible to do and the productivity of the people doing them. Bowman recognized the importance of developing software and data handling capabilities in support of Dionex's hardware. Bowman has also emphasized the importance of marketing support, working closely with customers to ensure that they were satisfied with the products they were using, and developing new applications for customers' areas of interest. He has stated that, in his opinion, what distinguished Dionex was that "we do provide a complete solutions approach for our customers. We don't just sell them hardware and walk away. We work with them to make sure that what we sell them makes them more effective and productive in their job." Through such improvements, Dionex was able to support much faster extraction of organic compounds for analysis from chemical mixtures, including complicated samples such as soils, polymers, and processed foods.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.